Blood Transplantation Overview

Principles

Definition

Blood transplantation is a research concept and academic field examining the comprehensive processes involved in the acquisition, preparation, and therapeutic administration of blood and blood components. It investigates the biological, logistical, ethical, and regulatory dimensions of blood product transfer, aiming to optimize safety, efficacy, and equitable access in medical interventions.

Ontological type

Immunologic Complications

Clinical Indications

Donor Selection

Key developments

Key Figures

Immunogenetic Engraftment Determinants era

E. Donnall Thomas [1], working across major centers such as Washington University in St. Louis [3] and the University of Washington [4] during this era, helped catalyze bone marrow transplantation as a clinical modality. His 1974 paper on the clinical manifestations of graft-versus-host disease in recipients of HL-A-matched marrow donors [6] highlighted how immunogenetic factors governed engraftment and GVHD risk, guiding donor selection and early immunomodulatory approaches. Jean E. Sanders [2], affiliated with the University of Washington [4] and the University of North Carolina at Chapel Hill [5] during this period, contributed multiple clinical transplant studies that advanced candidacy assessment and supportive care. Her work, including Marrow Transplantation for Acute Nonlymphoblastic Leukemia in First Remission [7], Marrow Transplantation in Thirty Untransfused Patients with Severe Aplastic Anemia [8], and Granulocyte Transfusions for the Prevention of Infection in Patients Receiving Bone-Marrow Transplants [9], helped shape engraftment outcomes and infection prophylaxis within the era's immunogenetic framework.

Standardization of Alternative Grafts era

John E. Wagner [1], affiliated with Rockefeller University [3] and the University of California, San Francisco [4], was a leading figure in cord blood transplantation during this era. His work documented the growth characteristics and expansion potential of cord blood for adult transplantation [8], compared unrelated donor cord blood with bone marrow in children [7], and reported outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia [9], collectively undergirding the era's move toward standardized cord blood grafts and broader donor access. D. Robert Sutherland [2], associated with the Institute of Cancer Research [5] and the University of Toronto [6], contributed to standardization efforts in this era. His key contribution centers on the ISHAGE Guidelines for CD34+ Cell Determination by Flow Cytometry [10], establishing standardized enumeration and quality-control benchmarks that enabled consistent dosing and safer use of alternative graft sources in this era.

Cyclophosphamide‑based Haploidentical Paradigm era

Paul J. Martin [1], a leading figure in this era, is associated with University of Washington [3] and the University of Minnesota [4]. His key contributions in this era include advancing chronic GVHD criteria through the NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report [7], Life Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell Transplantation [8], and Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti–T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease–Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation [9], which collectively refined outcomes reporting and strategies to balance GVHD and graft-versus-tumor effects in this era. Daniel J. Weisdorf [2], affiliated with Heidelberg University [5] and Boston University [6], contributed to these frameworks and translational insights shaping post-transplant outcomes. His contributions include the NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report [7], Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome [10], and Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia: Similar Outcomes Regardless of Donor Type [11], collectively guiding risk stratification and donor selection in cyclophosphamide-based haploidentical transplantation.